Randomized Controlled Trial
Copyright ©The Author(s) 2024.
World J Diabetes. Dec 15, 2024; 15(12): 2311-2321
Published online Dec 15, 2024. doi: 10.4239/wjd.v15.i12.2311
Table 1 Baseline characteristics of the patients, n (%)

Intervention (n = 42)
Control (n = 40)
P value
Gender male31 (73.8)33 (82.5)0.3421
Age, mean ± SD (years)56.62 ± 7.7656.68 ± 8.270.9752
DM
Type 15 (11.9)8 (20)0.3161
Type 237 (88.1)32 (80)
HbA1c, mean ± SD (%)7.93 ± 1.897.49 ± 1.710.4142
DM duration (years)14 (10)12 (15)0.7053
Oral hypoglycemics (years)10.5 (8)10 (9)0.9713
Subcutaneous hypoglycemics (years)6 (10)8.5 (20.5)0.0983
Insulin pump1 (2.4)2 (5)0.6114
Ulcer6 (14.3)1 (2.5)0.1104
Table 2 Range of motion examination, mean ± SD

Intervention (n = 42)
Control (n = 40)
P value
Ankle joint
D146.64 ± 11.747.9 ± 10.030.604
D1556.55 ± 11.6648 ± 9.99< 0.001
M649.4 ± 12.747 ± 9.250.332
D15-D19.9 ± 7.160.1 ± 3.26< 0.001
M6-D12.76 ± 7.26-0.9 ± 4.060.006
Subtalar joint
D121.43 ± 6.2223.13 ± 6.470.230
D1528.93 ± 4.4922.88 ± 6.29< 0.001
M625.4 ± 4.2823 ± 5.970.039
D15-D1 7.5 ± 5.12-0.25 ± 2.25< 0.001
M6-D13.98 ± 6.4-0.13 ± 3.49< 0.001
First metatarsophalangeal joint
D173.81 ± 17.0378.65 ± 19.520.234
D1583.88 ± 17.5180.63 ± 15.490.376
M675.55 ± 16.7777.5 ± 19.810.631
D15-D110.07 ± 18.661.98 ± 8.390.014
M6-D11.74 ± 19.72-1.15 ± 13.810.447
Table 3 Foot and ankle muscle strength examination, mean ± SD

Intervention (n = 42)
Control (n = 40)
P value
Dorsal flexors
D113.12 ± 4.4616.5 ± 4.18< 0.001
D1515.74 ± 4.716.6 ± 4.270.388
M613.79 ± 3.6515.75 ± 3.870.021
D15-D12.62 ± 1.690.1 ± 1.35< 0.001
M6-D10.66 ± 2.38-0.75 ± 1.940.004
Plantar flexors
D120.95 ± 6.1626.61 ± 5.78< 0.001
D1524.19 ± 6.0326.91 ± 5.880.042
M622.74 ± 5.5625.63 ± 5.660.022
D15-D13.24 ± 1.620.3 ± 1.48< 0.001
M6-D11.79 ± 2.18-0.99 ± 2.08< 0.001
Score of muscle strength
D113.93 ± 4.4110.33 ± 4.13< 0.001
D1512.48 ± 3.8410.3 ± 4.150.016
M612.76 ± 3.8210.53 ± 4.270.014
D15-D1-1.45 ± 1.42-0.03 ± 0.16< 0.001
M6-D1-1.17 ± 1.530.2 ± 0.56< 0.001